Table 1.
Percentage of survey responders (N = 12) expecting a benefit for the five functionalities of MRgRT compared to CBCT-guided photon or proton therapy for different areas in the body and corresponding pediatric tumor scenarios. A percentage of ≤25% (=3/12) was marked as ‘no’ benefit, a percentage between 25% and 75% was assigned to a ‘maybe benefit’ (in italic), and ≥75% (=9/12) as ‘expected clinical benefit’ (in bold).
| Brain | PTV margin reduction | Daily adaptation of the target volume delineation | Online replanning for optimal OAR sparing | Compensation for intrafraction motion | Functional imaging during the session |
|---|---|---|---|---|---|
| Primary RT, type diffuse midline glioma | 33% | 0% | 0% | 17% | 58% |
| Primary RT, type craniopharyngioma | 42% | 50% | 42% | 17% | 33% |
| Post-operative with tumor in situ, type posterior fossa ependymoma | 50% | 17% | 25% | 17% | 50% |
| Post-operative with tumor in situ, type craniopharyngioma | 42% | 42% | 42% | 17% | 33% |
| Post-operative without tumor in sity, type high-grade glioma | 33% | 25% | 25% | 17% | 50% |
| Craniospinal RT, no macroscopic tumor in situ | 8% | 0% | 8% | 25% | 17% |
| Craniospinal RT, with metastatic laesions in situ | 33% | 25% | 42% | 25% | 25% |
| Head & Neck | |||||
| Primary RT, type parameningeal rhabdomyosarcoma | 50% | 33% | 50% | 17% | 58% |
| Primary RT, type nasopharynx | 42% | 58% | 50% | 17% | 50% |
| Post-operative RT, type parotid gland | 33% | 0% | 25% | 17% | 8% |
| Post-operative RT, type neuroblastoma | 25% | 8% | 42% | 25% | 8% |
| Thorax | |||||
| Primary RT, type mediastinal germ cell tumor | 67% | 67% | 67% | 67% | 50% |
| Primary RT, type lymphoma | 75% | 67% | 67% | 67% | 50% |
| Post-operative RT, type Ewing sarcoma arising from rib | 50% | 33% | 33% | 67% | 8% |
| Whole lung RT with tumor in situ, type mets from Ewing or Wilms | 17% | 17% | 33% | 42% | 25% |
| Whole lung RT without tumor in situ, type Ewing or Wilms | 17% | 17% | 33% | 42% | 17% |
| Abdomen | |||||
| Primary RT, type rhabdomyosarcoma | 100% | 75% | 83% | 67% | 58% |
| Post-operative RT with tumor in situ, type neuroblastoma | 83% | 50% | 83% | 58% | 50% |
| Post-operative RT without tumor in situ, type Wilms tumor or neuroblastoma | 50% | 17% | 58% | 42% | 0% |
| Whole abdomen irradiation with tumor in situ, type rhabdomyosarcoma or desmoplastic small blue round cell tumor | 17% | 25% | 42% | 50% | 42% |
| Whole abdomen irradiation without tumor in situ, type Wilms tumor | 8% | 8% | 33% | 33% | 0% |
| Pelvis | |||||
| Primary RT, type Ewing of pelvic bones | 58% | 67% | 75% | 33% | 50% |
| Primary RT, type rhabdomyosarcoma of prostate/bladder region | 83% | 75% | 83% | 58% | 58% |
| Post-operative RT, type Ewing of pelvic bones | 17% | 17% | 42% | 17% | 17% |
| Post-operative RT, type rhabdomyosarcoma of prostate/bladder region | 50% | 50% | 67% | 58% | 17% |
| Extremities | |||||
| Primary or pre-operative RT, type rhabdomyosarcoma or Ewing sarcoma | 75% | 42% | 33% | 25% | 42% |
| Post-operative with tumor in situ, type rhabdomyosarcoma or Ewing sarcoma | 58% | 25% | 33% | 25% | 42% |
| Post-operative without tumor in situ, type rhabdomyosarcoma or Ewing sarcoma | 33% | 8% | 17% | 17% | 8% |